Radial Vs. State-Of-The-Art Femoral Access for Bleeding and Access Site Complication Reduction in Cardiac Catheterization (REBIRTH)

Purpose

This is a phase IV, prospective, open label, randomized-controlled study that will compare radial access with state-of-the-art femoral access in patients without ST-segment elevation acute myocardial infarction undergoing cardiac catheterization. Subjects will be randomized 1:1 into 2 treatment groups: radial access and state-of-the-art femoral access. Randomization will be performed in blocks of 50 per site. Similarly, a second sub-randomization will be performed in the femoral access group into use of 18 vs 21 gauge needles, also in a 1:1 fashion.

Conditions

  • Patient Satisfaction
  • Vascular Access Complication

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age 18 years and older - Undergoing diagnostic angiography for ischemic symptoms with possible PCI, or undergoing planned urgent or elective PCI - Has provided informed consent and agrees to participate - Patients must be equally eligible to undergo cardiac catheterization via radial or femoral access

Exclusion Criteria

  • Primary PCI for STEMI - Planned right heart catheterization - Valvular heart disease requiring valve surgery within 30 days after the index procedure - Hemodialysis access (arteriovenous fistula or graft) in the arm to be used for PCI in case of assignment to radial approach (the opposite arm may be used for radial access if a dialysis graft is present in one) - Peripheral arterial disease prohibiting vascular access - Presence of bilateral internal mammary artery coronary bypass grafts - International normalized ratio ≥1.5 while treated with oral vitamin K antagonists (i.e. warfarin) Receipt of oral factor Xa or IIa inhibitors ≤24 h before procedure - Planned staged PCI within 30 days after index procedure. - Any planned surgeries within 30 days after index procedure - Planned dual arterial access (for example for chronic total occlusion PCI) - Coexisting conditions that limit life expectancy to less than 30 days - Positive pregnancy test

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Active Comparator
Radial access
Radial access for cardiac catheterization. Radial access will be performed using ultrasound guidance and a micropuncture needle or catheter-over-needle system, as per the local standard of care.
  • Procedure: Radial Access
    Radial Access
Active Comparator
State-of-the-art femoral access
Femoral access for cardiac catheterization. Femoral access will be obtained using state-of-the-art techniques (ultrasound and fluoroscopic guidance for arterial puncture, immediate femoral angiography after obtaining access and use of a vascular closure device whenever possible).
  • Procedure: State-of-the-art femoral access with 18 gauge needle
    State-of-the-art femoral access with 18 gauge needle
  • Procedure: State-of-the-art femoral access with 21 gauge needle
    State-of-the-art femoral access with 21 gauge needle. For patients randomized to micropuncture (21G) the micropuncture wire must be advanced under fluoroscopy to avoid inadvertent wiring of side-branches.

Recruiting Locations

San Francisco VA Medical Center
San Francisco, California 94121
Contact:
Jeffrey Zimmet, MD, PhD
415-221-4810
jeffrey.zimmet@va.gov

Mayo Clinic Florida
Jacksonville, Florida 32224
Contact:
Federico Simon
904-953-4205
Simon.FedericoRey@mayo.edu

Joseph Maxwell Cleland Atlanta VA Medical Center
Decatur, Georgia 30033
Contact:
Nikki Leslie, RN
404-321-6111
nikki.leslie@va.gov

Minneapolis Heart Institute Foundation
Minneapolis, Minnesota 55407
Contact:
Bavana Rangan, BDS, MPH, CCRP
612-863-3852
bavana.rangan@allina.com

Oklahoma Heart Hospital
Oklahoma City, Oklahoma 73120
Contact:
Julia Myers, RN
405-608-1284
jmyers@okheart.com

More Details

Status
Recruiting
Sponsor
Minneapolis Heart Institute Foundation

Study Contact

Bavana Rangan, BDS, MPH, CCRP
612-863-3852
bavana.rangan@allina.com